- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01767363
WEUSKOP5723: Prostate Cancer Study
Prostate Cancer in Benign Prostatic Hyperplasia (BPH) Patients
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
A retrospective cohort study from 1992-2010 will be conducted using data from 4 Kaiser sites: Kaiser Permanente Southern California (KPSC), Kaiser Permanente Northern California (KPNC), Kaiser Permanente Northwest (KPNW), and Kaiser Permanente Colorado (KPCO). Men treated with BPH medications, 5ARIs (with and without concomitant and/or previous alpha-blocker use) will be compared to men treated with alpha-blockers. A matched design will be used with each man treated with 5ARIs being matched with 5 or 6 men treated with alpha-blockers. Men 50 years or older at the time of their first prescription for a study defined BPH medication, initiating treatment between 1992 and 2008 with at least 1-year of coverage in the healthcare system before the first prescription for BPH medication and at least 3 consecutive prescriptions (90 days of supply) for a BPH medication will be eligible for inclusion in the study. Men with a diagnosis of prostate cancer any time before the first prescription for BPH medication, having a diagnosis of prostate cancer within 3 months after initiation of their first BPH medication, and those treated with finasteride 1mg prior to their BPH medication will be excluded from the study. 5ARI initiators will be matched to alpha-blocker users in a ratio of 1:5 or 1:6 to yield an overall matching ratio of 1:5.4. Matching factors include age (+/- 1 year), timing of BPH treatment initiation (+/- 1 year), race, and duration of prior use of alpha-blockers. Based on the feasibility study from KPSC, there will be approximately 284,000 men treated with BPH medications meeting eligibility criteria for inclusion in the study sample.
The data will be analyzed using Kaplan Meier curves comparing the 5ARI vs alpha-blocker users for the primary and secondary study outcomes, without any adjustments. Additionally, a plot of cumulative incidence, adjusting for competing risks of death, will be constructed allowing for the investigation of the effect of competing risks on the Kaplan-Meier probability estimates. Crude mortality rates and incidence rates of metastatic cancer will be calculated. Cox proportional hazard regression models will be fit to compare the primary and secondary outcomes between groups using hazard ratios, while adjusting for pre-treatment characteristics.
Tipo di studio
Iscrizione (Effettivo)
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Patients that are Male
- Patients that have a new prescription for BPH medication (5ARI and/or alpha-blocker) in 1992 or later that is identified as appropriate treatment for BPH/LUTS from the KP National Pharmacy guidelines.
- Patients with a treatment with BPH medication must be initiated prior to Jan1, 2008.
- Patients age 50 years or older at time of treatment with 5ARI or alpha-blocker.
- Patients with at least 1-year of coverage in the healthcare system before the first prescription for BPH medication (5ARI and/or alpha-blocker).
- Patients with at least 3 consecutive prescriptions (90 days of supply) for a BPH medication (5ARI and/or alpha-blocker).
Exclusion Criteria:
- Patients with a diagnosis of prostate cancer any time before the first prescription for BPH medication (5ARI and/or alpha-blocker).
- Patients with a dagnosis of prostate cancer within 3 months after first BPH medication (5ARI and/or alpha-blocker)
- Patients treated with Finasteride 1mg prior to BPH medication. Finasteride 1mg is the dose approved for androgenic alopecia and as the target population for this study is men with treated BPH, we will exclude all men treated with the 1mg dose.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Retrospettiva
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
5-alpha reductase inhibitors with or without alpha-blockers
Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
|
Use of 5-alpha reductase inhibitors over the course of the study period.
Use of alpha-blockers over the study period.
|
Alpha-blockers
Men using alpha-blockers over the course of the study period.
|
Use of 5-alpha reductase inhibitors over the course of the study period.
Use of alpha-blockers over the study period.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The primary outcome is prostate cancer related mortality.
Lasso di tempo: 17 years
|
Cause of death codes from death certificates, along with an electronic algorithm using pre-defined decision points, will be used to classify cause of death.
Chart review will be performed to further validate cause of death.
|
17 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
One of the secondary outcomes is all cause mortality. Death information will be derived from several sources including membership files, state death records and the Social Security Index.
Lasso di tempo: 17 years
|
17 years
|
|
One of the secondary outcomes is the combined endpoint of prostate cancer mortality or metastatic prostate cancer.
Lasso di tempo: 17 years
|
Metastatic prostate cancer will be identified using data recorded in cancer registries and with an algorithm based on patient medical records.
|
17 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie genitali, maschio
- Malattie della prostata
- Neoplasie prostatiche
- Iperplasia prostatica
- Iperplasia
- Effetti fisiologici delle droghe
- Antagonisti adrenergici
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Ormoni, sostituti ormonali e antagonisti ormonali
- Antagonisti ormonali
- Inibitori della sintesi di steroidi
- Alfa-antagonisti adrenergici
- Inibitori della 5-alfa reduttasi
Altri numeri di identificazione dello studio
- 116059
- WEUSKOP5723 (Altro identificatore: GSK)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su 5-alpha reductase inhibitors
-
H. Lee Moffitt Cancer Center and Research InstituteCompletatoCarcinoma, cellule squamose | Carcinoma a cellule squamose della pelleStati Uniti
-
M.D. Anderson Cancer CenterSchering-Plough; Eisai Inc.Terminato
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.CompletatoRecettore per gli estrogeni negativo | HER2/Neu negativo | Recettore del progesterone negativo | Cancro al seno triplo negativo | Cancro al seno in stadio anatomico IV AJCCStati Uniti
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ReclutamentoCancro al seno in stadio anatomico IV AJCC v8 | Carcinoma mammario triplo negativo metastatico | Carcinoma mammario triplo negativo non resecabileStati Uniti